Potential sources of bacteria causing ventilator-associated pneumonia. Bacteria residing in the oropharynx and gastrointestinal tract can contaminate the subglottic secretion pool, as demonstrated. Subglottic secretions above the endotracheal tube cuff are aspirated into the trachea and disseminated into the distal airways and lung parenchyma by the force of the ventilator (inset).
Recommended empirical antibiotic therapy for ventilator-associated pneumonia. Recommendations are adapted from the American Thoracic Society consensus statement of 1995.85 Risk factors consist of previous use of antibiotic drugs, use of corticosteroids, clinical shock, immunosuppression, and neutropenia. Asterisk indicates β-lactam±β-lactamase inhibitors, imipenem, meropenem, ceftazidime, cefoperazone sodium, cefepime, and aztreonam (avoid a combination of aztreonam and an aminoglycoside if gram-positive cocci are suspected); dagger, use only fluoroquinolones with reliable antipseudomonal activity. See the "Antibiotic Selection" subsection for details.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Morehead RS, Pinto SJ. Ventilator-Associated Pneumonia. Arch Intern Med. 2000;160(13):1926–1936. doi:10.1001/archinte.160.13.1926
Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
Ventilator-associated pneumonia is a common complication in intensive care units, occurring in 9% to 24% of patients intubated for longer than 48 hours. Because of this large disease burden and the resultant attributable morbidity and mortality, there is great interest in accurately diagnosing, treating, and preventing this complication. More severely ill patients tend to develop ventilator-associated pneumonia, and identified risk factors include prolonged mechanical ventilation, reintubation after failed extubation, and a few other clinical variables. The efficacy of diagnostic and preventive strategies is somewhat controversial. Diagnosis by invasive methods requires a considerable commitment of resources but can potentially reduce cost of care; however, mortality benefit from this approach has not been demonstrated. As such, in most institutions, ventilator-associated pneumonia is best diagnosed using traditional clinical criteria. Prompt administration of appropriate antibiotics seems to be the only intervention that alters outcome once the diagnosis is established. Several strategies seem to reduce pneumonia incidence; however, mortality and cost benefits have yet to be convincingly shown.
Ventilator-associated pneumonia is defined as parenchymal lung infection occurring more than 48 hours after initiation of mechanical ventilation. This serves to differentiate this disorder from community-acquired pneumonia and highlights pathogenic features peculiar to mechanically ventilated patients. A recent multicenter European study1 has shown that pneumonia is now the most common infection acquired in the intensive care unit (ICU), and when acquired during mechanical ventilation it has an associated mortality of 24% to 71%.2-10 A vast literature has accumulated concerning all facets of this disease, especially regarding the efficacy of available diagnostic methods and putative preventive measures. This article reviews the current state of the art with emphasis on diagnosis, treatment, and prevention strategies.
We searched the English-language literature using the MEDLINE database from 1966 to 1998 using search terms ventilator-associated pneumonia and nosocomial pneumonia. Additional articles were identified by reviewing the reference lists of retrieved articles. We selected articles containing information about the epidemiology, pathogenesis, diagnosis, management, and prevention of ventilator-associated pneumonia in adults. In evaluating this literature, meta-analyses, prospective cohort studies, and randomized controlled trials were given preference for inclusion; studies with less rigorous methods were excluded unless no data from preferred sources were found. Concerning interventions designed to prevent ventilator-associated pneumonia, final recommendations incorporate well-established guidelines for grading scientific evidence for medical practice,11 adapted as follows: grade A, recommendation based on 1 or more randomized controlled trials or meta-analysis in which the lower limit of the confidence interval for the treatment effect exceeds the minimally important clinical benefit; grade B, recommendation based on 1 or more randomized controlled trials or meta-analysis in which the lower limit of the confidence interval for the treatment effect overlaps the minimally important clinical benefit; and grade C, recommendation based on evidence from nonrandomized trials, case series, or expert opinion.
Gram-negative bacillus pneumonia became recognized as a significant cause of morbidity and mortality in hospitalized patients during the 1950s,12,13 coinciding with increasing use of mechanical ventilation and antibiotic drugs. Contaminated respiratory care equipment was initially implicated as the source of these pathogens; however, despite implementation of infection control measures, pneumonia has remained the most common ICU-acquired infection,1 with an incidence of 9% to 24% in patients mechanically ventilated for longer than 48 hours.3,6-9
The risk of developing ventilator-associated pneumonia relates to host factors and to the duration and intensity of exposure to potential pathogens. Single-center multivariate analyses6-8,14,15 have implicated prolonged mechanical ventilation and reintubation as risk factors; however, not all studies have agreed, and 2 studies7,15 reached discordant conclusions regarding previous antibiotic use. A recent multicenter Canadian study16 evaluated 1014 mechanically ventilated patients and found the following independent predictors of ventilator-associated pneumonia: a primary diagnosis of burns, trauma, central nervous system disease, respiratory tract disease, or cardiac disease; witnessed aspiration; mechanical ventilation within the previous 24 hours; and use of paralytic agents. Two other important findings of this analysis are (1) a rising daily risk for pneumonia until the fifth day of mechanical ventilation, with subsequent decline, and (2) a protective effect of systemic antibiotic therapy. Factors not assessed in this study but found to be predictive in other analyses include low endotracheal tube cuff pressure,15 transport outside the ICU,14 and supine body position.7 Although authors17 have identified recent surgery and altered sensorium as factors predisposing to pneumonia in mixed populations of ventilated and nonventilated ICU patients, studies6-8,16 excluding spontaneously breathing patients have consistently been unable to demonstrate this relationship, suggesting that intubation and mechanical ventilation obviate these risks.
Respiratory failure combined with critical illness frequently culminates in pneumonia, but accurately determining whether pneumonia is present can be difficult, especially in the setting of acute respiratory distress syndrome. Standard clinical methods are insensitive in unequivocally diagnosing ventilator-associated pneumonia; positive pleural fluid culture or radiographic cavitation is present in only a minority of patients,18-21 and blood cultures in this setting are positive in 10% or less.6,8,9,18 Studies22,23 using pulmonary histological patterns as a gold standard comparison reveal that clinical acumen is incorrect in determining the presence or absence of ventilator-associated pneumonia in up to one third of patients; alternative pathological diagnoses in this situation include atelectasis, infarction, hemorrhage, and fibrosis.22 These data suggest the need for improved diagnostic methods, and, in the pursuit of more accurate diagnosis, specific features of ventilator-associated pneumonia pathogenesis become important.
Events important in the progression to pneumonia in intubated patients begin with oropharyngeal colonization by potentially pathogenic bacteria.24,25 In this setting, endotracheal tube placement creates an abnormal continuum between the upper airway and the trachea and establishes a subglottic reservoir of secretions rich in bacterial pathogens. Secretions in this subglottic pool are aspirated into the trachea26,27 and become part of the biofilm lining the endotracheal tube.28 This biofilm can then be disseminated into the lung by the ventilator.29 In addition, organisms within the stomach can also contaminate the subglottic secretions. These events are summarized in Figure 1.
Although bacterial colonization of the lower respiratory tract is an essential step in pneumonia development, tracheal aspirate cultures unreliably predict infection, even if a quantitative culture threshold of greater than 103 colony-forming units (CFUs)/mL is stipulated as significant.30-32 Given this problem, investigators have sought to correlate pneumonia with the presence of a "significant" level of bacterial growth from the distal airways and lung parenchyma. Autopsies performed on patients dying after prolonged mechanical ventilation reveal 3 distinct lung histological patterns: tracheobronchitis, bronchopneumonia, or bronchiolitis (inflammation of small airways without pneumonia).33 In the absence of antibiotic treatment, histological pneumonia is associated with a bacterial burden greater than 103 CFU per gram of lung tissue,34,35 suggesting a quantitative threshold to diagnose pneumonia. However, studies22,33,34,36-38 including patients receiving antibiotic medications reveal a highly variable ability to predict pneumonia for quantitative cultures above threshold: sensitivity, 11% to 100%; specificity, 45% to 100%. Thus, the assumption that quantitative bacteriologic study accurately predicts histological patterns may be incorrect in certain clinical settings.
Given the limitations of standard clinical methods and the fact that lung biopsy is often not feasible or definitive in this setting,38 an easily applicable diagnostic method has been sought. The bronchoscopically deployed, double-sheathed protected specimen brush catheter is the best-studied invasive technique, and a quantitative bacterial count of 103 CFU/mL or greater is an accepted threshold to diagnose pneumonia.22,34,36 Bronchoalveolar lavage is used by a comparable number of investigators,22,33,34,39-42 and the most common reported bacterial colony count indicative of pneumonia is 104 CFU/mL or greater. The attraction of this latter technique rests on the ability to immediately examine Gram stains of retrieved lung cells in which the finding of intracellular bacteria is predictive of pneumonia; 2 recent studies43,44 evaluating this technique report diagnostic specificity approaching 90%.
Invasive testing is subject to confounding variables. Quantitative bacteriologic study in patients with positive, but subthreshold, culture are often not reproducible on repeated testing,45-47 and Gram staining of retrieved lung cells is insensitive in the setting of concurrent antimicrobial therapy.48-51 As such, decisions to withhold antibiotic drugs based on subthreshold, positive quantitative culture should be made carefully. Notwithstanding, there are data37,40 supporting the validity of invasive testing in the presence of antimicrobial drugs, provided therapy is not changed within 48 to 72 hours of testing.
Attempting to avoid the high cost and logistic difficulty of bronchoscopy, the protected specimen brush catheter and bronchoalveolar lavage (the latter by a specially designed catheter) have been applied by inserting catheters directly through the endotracheal tube. Several studies34,49,52-54 have reported operating characteristics similar to bronchoscopically based procedures, with one study54 demonstrating safety in a series of 72 procedures performed by trained respiratory therapists. In addition to these modifications, quantitative culture of suctioned sputum obtained without use of a specialized catheter has been shown30-32,55 to identify pathogens with an equal or greater sensitivity compared with invasive methods, but lower specificity attends its use.
Despite claims of greater accuracy for invasive testing and a published decision analysis56 suggesting mortality benefit using an invasive method–based management algorithm, no conclusive evidence of improved mortality exists. Mechanically ventilated patients with a constellation of clinical findings suggestive of pneumonia will have this diagnosis confirmed by invasive testing in about half of the episodes.5,43,57,58 However, clinical suggestion alone seems to confer higher mortality to patients, even if results of invasive testing are negative.5,57,58 The study protocols of most investigations of invasive pneumonia diagnosis stipulate that patients suspected of having pneumonia receive empirical antibiotic therapy while awaiting invasive test results. As such, negative invasive test results ostensibly identify patients who can have antibiotic drug therapy safely discontinued, whereas positive test results indicate a requirement for continued treatment. Despite the lack of demonstrable mortality benefit, this approach seems to reduce antimicrobial use59-61 and might lead to reduced total cost of care and less antibiotic resistance. Two studies60,61 analyzing total cost of care of invasive diagnosis reached discordant conclusions principally on the basis of antimicrobial cost difference; both used bronchoscopy, adding substantially to the cost of diagnosis. An interesting finding in these studies is that physicians often do not discontinue antibiotic drug therapy in the setting of negative or subthreshold quantitative cultures.59,61,62 Heyland and coworkers59 found that invasive testing led to reduced antibiotic use and greater confidence in doing so; however, as suggested by other studies,61,62 physicians use these tests as part of a general clinical gestalt in making decisions to stop or change antibiotic use. This variability in physician practice makes the cost outcome resulting from invasive testing protocols difficult to predict.
In the final analysis, the diagnosis of ventilator-associated pneumonia involves 2 steps: (1) deciding whether pneumonia is present and (2) identifying a microbiologic agent to target antibiotic therapy. In that invasive diagnosis requires a substantial institutional commitment in resources, this approach is beyond the abilities of many institutions. The traditional method of clinical diagnosis continues to be the standard of care in the United States, and support for this "usual care" approach derives from the demonstrated diagnostic accuracy of published clinical scoring systems compared with invasive methods.22,33,38,63 Although not proven, these data suggest that experienced clinicians might perform as well as invasive methods. After pneumonia is diagnosed clinically, refinements in antibiotic selection should rely on the culture of endotracheal aspirate because this method identifies potential pathogens at least as well as invasive methods.30-32,35,38,49,64
There are no placebo-controlled trials of the treatment of ventilator-associated pneumonia; presumption of benefit is based on the underpinning principles of antibiotic therapy, data demonstrating attributable morbidity and mortality,4,65-68 and the poor outcome of patients given antibiotic drugs that do not cover causative bacteria (Table 1).4,8,9,57,62,72,73
Although it is clear that the presence of ventilatory-associated pneumonia adversely affects outcome, results of investigations2-4,65-67 attempting to document this excess morbidity and mortality as attributable to the pneumonia alone have been somewhat divided. In an effort to clarify this issue, Heyland and colleagues68 used a prospective case-matching scheme that included factors such as duration of ventilator assistance, initial illness severity, and primary diagnosis used in other studies, but they also matched patients by organ dysfunction index the day before pneumonia development to further ensure that both groups were similar at pneumonia onset. In this multicenter study, mortality was higher for the pneumonia group (23.7%) than for the control group (17.9%), but the attributable mortality, 5.8% (95% confidence interval, −2.4% to 14.0%), and relative risk increase for death, 32.3% (95% confidence interval, −20.6% to 85.1%), were not statistically significant. Nevertheless, ventilator-associated pneumonia was associated with significantly greater ICU length of stay (mean difference, 4.3 days; 95% confidence interval, 1.5-7.0 days; P<.001), and this was seen in both survivors and nonsurvivors. In addition, only the medical patients had excess morbidity and mortality. Taken together, the evidence clearly points to ventilator-associated pneumonia as an independent predictor of adverse outcome for patients as a whole; however, this effect is not equal in all populations, as medical patients seem disproportionately affected.
The microbiologic isolates of ventilator-associated pneumonia reflect a broad array of bacteria that vary with the particular hospital and ICU studied. Published series using invasive methods reveal gram-negative bacilli as the most common isolates found above predefined diagnostic thresholds (Table 2). Polymicrobial episodes are also common.3,9,33,72,74-76 Anaerobic bacteria were previously thought to be important in the pathogenesis of ventilator-associated pneumonia, but this has been recently questioned. Using invasive testing, Dore and colleagues76 isolated anaerobes in only 23% of patients with confirmed ventilator-associated pneumonia (13% as the sole pathogen), and Marik and Careau77 were unable to identify pathogenic anaerobes in 143 suspected cases. These data, combined with the rare isolation of anaerobes in postmortem lung biopsy specimens,22,34,36 point toward a minor role in most instances. In addition, nosocomial pneumonia caused by Legionella species can occur in institutions with contaminated water sources; ventilated patients can then be exposed if tap water is used for respiratory care procedures.78-81
Appropriate antibiotic therapy for ventilator-associated pneumonia can be defined as treatment with antimicrobial drugs that cover all likely pathogens isolated from respiratory tract secretions. Caveats to this statement include that (1) samples sent for culture should reflect lower respiratory tract secretions, ie, more than 25 granulocytes and less than 10 epithelial cells per low-power field and (2) less virulent organisms such as vancomycin-resistant enterococci and coagulase-negative staphylococci might not be pathogenic; this is especially germane when more virulent bacteria are concurrently isolated (the more likely culprit) and risk factors for invasive disease are absent.
Given these caveats, one important lesson from recent studies is that antibiotic coverage should be given early after infection is suspected, and the spectrum of this agent(s) should address all reasonably suspected pathogens. Several studies57,69,71 have demonstrated that the need to change antibiotic drugs after culture data becomes available identifies a subgroup of patients with higher mortality. Moreover, Luna and colleagues58 noted that the mortality benefit of appropriate antibiotic coverage pertained only to that treatment present before invasive diagnostic testing, suggesting that an important time window exists after which antibiotic treatment, regardless of activity, is less effective. As such, the single most important management decision after a clinical diagnosis of pneumonia is whether antimicrobial activity against potentially resistant organisms such as Pseudomonas aeruginosa, Acinetobacter species, and Stenotrophomonas maltophilia is warranted. These organisms occur later in the course of mechanical ventilation,82 usually in the presence of previous antibiotic therapy,69,83,84 and are independently associated with poor outcome.4,8,9,57,62,72,73 Trouillet and coworkers75 prospectively studied 135 patients with ventilator-associated pneumonia, comparing episodes caused by these high-risk bacteria (including methicillin-resistant Staphylococcus aureus) with those secondary to other pathogens. By multivariate analysis, duration of ventilation before pneumonia onset and previous broad spectrum antibiotic drug use were the only factors associated with high-risk organisms. Moreover, in 84 patients ventilated for 7 days or longer with previous antibiotic exposure, an empirical triple-drug regimen including vancomycin was required to obtain acceptable antimicrobial activity in 88% of episodes. With this sort of data in mind, the American Thoracic Society guidelines85 recommend expanded coverage for these organisms in the presence of 5 days or more of hospitalization before pneumonia onset, previous antibiotic treatment, corticosteroid use, structural lung disease, and immunosuppression.
Empirical antibiotic medication selection should take into account risk factors, as outlined above, especially time of pneumonia onset. Patients with late-onset pneumonia (≥5 days of hospitalization) or risk factors should be covered with antibiotic drugs with acceptable antipseudomonal activity (Figure 2), including select fluoroquinolones, aminoglycosides, β-lactams with or without β-lactamase inhibitors, and third-generation cephalosporins, as well as imipenem, meropenem, and aztreonam. Monotherapy with these agents (excluding aminoglycosides) is associated with clinical failure in 15% to 29% of patients86-89; however, because of exclusion of the most severely ill patients in some of these trials, the failure rate experienced in clinical practice might be higher. High-risk organisms constitute most clinical failures, as evidenced by the ability to eradicate P aeruginosa in only 34% of pneumonic episodes in one study.90 Multicenter randomized trials have compared imipenem with ciprofloxacin,90 piperacillin-tazobactam,86 and ceftazidime87 as single-agent therapy but did not demonstrate clear-cut superiority of any one agent; however, use of piperacillin-tazobactam seemed to be more efficacious against P aeruginosa.86 To minimize clinical failure associated with high-risk pathogens, 2 antimicrobial agents of different action mechanisms are recommended until culture results are available. A traditional choice in this regard has been an extended spectrum β-lactam plus an aminoglycoside; however, newer agents also have excellent activity (Figure 2). Limited information suggests that piperacillin-tazobactam may be the preferred agent against high-risk organisms; one recent multicenter study91 comparing a combination of piperacillin-tazobactam plus amikacin with ceftazidime plus amikacin revealed a 2-fold higher rate of clinical and microbiologic failure with the ceftazidime-containing regimen (26% vs 46%; P=.023). The reasons for this failure were a 2-fold higher rate of both superinfection and persistence and relapse of the initial infecting organism. Given that failure to eradicate high-risk organisms might be responsible for most recurrent ventilator-associated pneumonia,92 and the risk of inducing resistance during cephalosporin monotherapy,93 it seems most reasonable to use noncephalosporin antibiotics for high-risk organisms (ie, P aeruginosa, Acinetobacter species, Enterobacter species, and S maltophilia) or a second agent to prevent this occurrence.
Empirical antibiotic selection should also be cognizant of local bacterial resistance patterns and the heightened risk of inadequate therapy in more severely ill patients. A recent study94 demonstrated significant variability in pathogens in 3 institutions such that in 1, inadequate empirical therapy would have been prescribed for almost 20% of patients if standard guidelines had been followed without regard to local bacterial patterns. In addition, methicillin-resistant S aureus is prevalent in certain institutions with risk factors similar to high-risk gram-negative bacilli95; in these institutions, the addition of vancomycin to the empirical regimen should be considered in patients at risk for early death. Intravenous administration should be the rule during the initial treatment phase in all but the most stable patients to avoid irregular gastrointestinal tract absorption that might accompany critical illness.
Antibiotic resistance is a serious emerging problem, and data from the National Nosocomial Infectious Surveillance System96 document higher levels of antibiotic resistance in patients treated in ICUs compared with non-ICU hospitalized and ambulatory patients. Because this problem is largely related to antimicrobial exposure, judicious antimicrobial use in the ICU should be a major concern in all management decisions. Extended spectrum lactam agents are particular likely to induce bacterial resistance to antibiotic drugs. Induction of β-lactamases after β-lactam use97-99 and alterations in bacterial membrane permeability after imipenem use100,101 have received considerable attention; however, no antibiotic class is immune to this phenomenon. Given these facts, antibiotic resistance should be minimized by using agents with the narrowest activity spectrum after culture and sensitivity data become available and by stopping antimicrobial therapy when infection is reasonably excluded. Other strategies to potentially prevent resistance include antibiotic class restriction100 and scheduled changes in antibiotic class used for empirical therapy in ICUs.102
Given the considerable attributable morbidity of ventilator-associated pneumonia and the fiscal loss to hospitals caring for these patients,103,104 prevention has become a major focus. Published guidelines105-107 emphasize the importance of infection control and surveillance, and implementation of a nosocomial pneumonia prevention policy has been shown to decrease disease incidence.108,109 Bacterial colonization of the lower respiratory tract of mechanically ventilated patients is the targeted event of most preventive strategies. Several of the more controversial topics are discussed in the following subsections (Table 3); the reader is directed to a recent comprehensive review for further information.110
Depending on primary disease and previous patient locale, bacterial colonization of the trachea is recognized in up to three quarters of patients on initial sampling after ICU admission.111-113 Studies are somewhat divided as to the source of these microbes: some data112 support between-patient transmission and others114-118 suggest that most pathogens are endogenous flora. Nevertheless, simple infection control measures such as hand washing are important,119 and an outbreak should prompt policy reevaluation.120-122
Selective decontamination of the aerodigestive tract with topically applied antibiotic drugs reduces the gastric bacterial burden and prevents tracheobronchial colonization and ventilator-associated pneumonia.123-128 Factors against routine use are the marginal mortality benefit for ventilated patients as a whole,127-129 cost of application, and risk of inducing antibiotic resistance.127,130,131 Moreover, studies reporting these finding have variously decontaminated the stomach alone, stomach and oropharynx, or both with the addition of a parenteral antibiotic drug, making the most appropriate approach unclear. Nevertheless, a subset of severely ill patients seem to derive benefit, as suggested by a reanalysis132 of previously performed studies and a recent study124 demonstrating reduced total cost of care. At present, despite reduced pneumonia incidence, more cost-benefit data are needed before selective decontamination is widely recommended.
High gastric pH is associated with increased numbers of gastric bacteria,133-135 and pH-altering drugs (antacids and histamine2 antagonists) are frequently administered to mechanically ventilated patients, potentially increasing the gastric bacterial burden. The association between treatment with pH-altering agents and nosocomial pneumonia, especially events occurring after 4 days of ventilation, has been suggested.136-138 However, meta-analyses139,140 reveal only a trend toward pneumonia reduction with non–pH-altering therapy, and a recent multicenter study141 of 1200 mechanically ventilated patients did not show a statistical difference. The poor correlation between pH-altering therapy and pneumonia is likely due to the intrinsically high gastric pH present in many critically ill patients137,142 and the fact that the stomach is the source of pathogens in only a few patients.143 Bacteria isolated from the trachea of mechanically ventilated patients arrive by different routes.111,112,142,144Pseudomonas aeruginosa, eg, most commonly appears de novo in the trachea and therefore is unlikely to be affected by gastric pH, in contrast to the Enterobacteriaceae, which are often first found in the stomach.111,145 Consistent with these findings, the delivery site and method of enteral feeding have not convincingly altered the incidence of nosocomial pneumonia,146-148 although postpyloric feeding could theoretically reduce colonization by gastric bacteria.
Airway management strategies have been studied in relation to pneumonia prevention and are the subject of a recent review.149 Two studies150,151 evaluating an endotracheal tube allowing removal of subglottic secretions demonstrated reduced incidence of pneumonia. Nasal endotracheal tubes have a higher incidence of radiographic sinusitis152 and may predispose to pneumonia. Holzapfel and colleagues153 reported a nonsignificant trend toward lower pneumonia incidence in orotracheally (6%) than nasotracheally (11%) intubated patients (P=.11) and in a subsequent study154 demonstrated a reduction in ventilator-associated pneumonia in nasotracheally intubated patients by using an aggressive diagnostic and treatment protocol for nosocomial sinusitis. In addition, supine position has been significantly associated with the occurrence of ventilator-associated pneumonia,7 probably because of increased aspiration into the respiratory tract, a preventable phenomenon if patients are treated upright at 45°.155,156
There is an increasing emphasis on noninvasive ventilation in the management of acute respiratory failure of diverse etiologies. Emerging data157-160 suggest that patients who tolerate noninvasive ventilation might have a lesser incidence of nosocomial pneumonia than those tracheally intubated. Moreover, because it seems that failed extubation and reintubation are also associated with an increased risk of pneumonia,8,161 management of respiratory failure without tracheal intubation holds promise regarding pneumonia prevention.
Several respiratory care practices have been the subject of study. Two recent reviews149,162 of ventilator circuit change frequency confirm that changes more often than every 7 days are unnecessary and may increase the risk of pneumonia. Despite the lack of definitive trials, heat and moisture exchangers and kinetic bed therapy also seem to reduce the incidence of pneumonia,149 but closed endotracheal tube suctioning systems do not demonstrably alter this occurrence.163,164 Larger, prospective trials are still needed to identify which of these interventions are cost-effective and which patient subgroups are most likely to benefit.
Ventilator-associated pneumonia is common in mechanically ventilated, critically ill patients, and higher severity of illness, prolonged mechanical ventilation, and intrinsic lung disease increase the risk of this complication. Invasive study of the lower respiratory tract in these patients has led to a better understanding of the pathogenic events leading to pneumonia but has not convincingly altered mortality or cost of care. Because inappropriate antibiotic drug therapy and the presence of high-risk organisms correlate with mortality secondary to ventilator-associated pneumonia, empirical antibiotic coverage should include agents with activity against P aeruginosa and related bacteria in the presence of prolonged mechanical ventilation and/or other risk factors. Efforts targeted at prevention have identified several respiratory care and airway management practices that seem to be efficacious. Selective decontamination of the aerodigestive tract also reduces pneumonia incidence but has not yet convincingly been shown to alter mortality or cost of care. Future investigations should include more outcomes assessments of newer diagnostic and preventive methods.
Accepted for publication January 10, 2000.
We thank Rolando Berger, MD, and Eric Bensadoun, MD, for review of the manuscript and helpful suggestions and Martha Cooper for the illustrations.
Reprints not available from the authors.
Create a personal account or sign in to: